Form D · Biotechnology

Delfi Diagnostics, Inc.

Palo Alto, CA · CIK 0001783735

Offering snapshot reported Dec 18, 2025 · SEC filing

Reported sold
$34.3M
Offering amount: $60M
Investors reported
50
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Dec 1, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 18, 2025Initial$34,333,315No comparison50SEC filing
Jul 25, 2022Initial$224,999,876No comparison44SEC filing
Jan 27, 2021Initial$101,074,986No comparison25SEC filing
Aug 27, 2019Initial$5,500,000No comparison7SEC filing
Aug 13, 2019Initial$15,343No comparison9SEC filing

Offering details

Securities
Debt
Exemptions
06b
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-567314

Source: Form D, filed Dec 18, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Peter B. Bach Executive
Jennifer Buechel Executive
Nicholas Dracopoli Executive
Michael Dybbs Director
Rishi Gupta Director
Elizabeth Homans Director
Justin Kao Director
Douglas Schenkel Executive
Amoolya Singh Executive
Lee Ann Smith Freeman Executive
William Stevens Executive
Susan Tousi Director, Executive
Jacob Van Naarden Director
Victor Velculescu Director
Greg Yap Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1810 Embarcadero Road Suite 100
Palo Alto, CA, 94303